{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-26-004628","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2026-09-28T12:46:22+00:00","discovered_at":"2026-09-28T12:50:57.176664+00:00","generated_at":"2026-10-12T13:32:10.997762+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Silexion reports positive preclinical findings for SIL204 showing lipoprotein-mediated uptake in KRAS-driven cancers","bullets":["SIL204 produced robust, dose-dependent mutant KRAS gene silencing in carrier-free assays; serum lipid depletion significantly reduced knockdown efficiency (P < 0.001).","Exogenous human LDL did not alter silencing potency versus complete serum alone, indicating physiological lipoprotein levels suffice without artificial nanoparticles.","CSDO Mitchell Shirvan cited LDL receptor upregulation in cancer cells; CEO Ilan Hadar highlighted the Phase 2/3 pancreatic program and systemic subcutaneous delivery.","Silexion is advancing SIL204 through Phase 2/3 in locally advanced pancreatic cancer, with site initiation at Tel Aviv Sourasky Medical Center and regulatory clearances in Germany."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-26-004628","json":"https://secwatch.observer/filing/0001178913-26-004628.json","markdown":"https://secwatch.observer/filing/0001178913-26-004628.md","text":"https://secwatch.observer/filing/0001178913-26-004628.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326004628/0001178913-26-004628-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326004628/zk2636165.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T13:32:10.997762+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}